IDEXX Laboratories, Inc.
IDXX
$698.02
-0.65%
IDEXX Laboratories develops, manufactures, and distributes diagnostic products, equipment, and services for companion animals and livestock, spanning in-clinic chemistry and hematology analyzers, single-use rapid test kits, reference laboratory services, and veterinary practice-management software, with roughly 35% of revenue generated outside the United States. The company is the dominant platform in veterinary diagnostics, distinguished by a razor-and-blade model in which instrument placements drive high-margin recurring consumable and reference-lab revenue, reinforced by deep workflow integration through its software and a scale advantage no competitor approaches. The current investor debate centers on whether IDEXX can sustain double-digit recurring diagnostics growth against a softer veterinary clinic-visit backdrop, following Q3 2026 revenue growth of roughly 10% alongside a raised EPS outlook but a trimmed margin forecast that raised questions about the durability of operating leverage and the role of buybacks in supporting per-share results. Sentiment has swung sharply positive into November, with the stock gapping higher after the Q3 print, yet the longer-term narrative remains contested given a still-negative one-year return and persistent concern over elevated valuation multiples.…
IDXX
IDEXX Laboratories, Inc.
$698.02
Related headlines
Investment Opinion: Should I buy IDXX Today?
Rating: Hold with a constructive bias. The core thesis is that IDEXX remains a premium-quality, capital-light compounder — ~10% recurring diagnostics growth, 62.94% gross margin, 33.14% operating margin, 65.99% ROE, and $1.30 billion of trailing free cash flow — but the 33.43% one-month post-earnings re-rating has pulled the $676.04 price to within ~6.1% of the $717.17 average analyst target, leaving an asymmetric risk/reward skewed by a 51.37x trailing PE. The consensus 'buy' (9 Buy, 4 Hold, 1 Sell; mean score 2.14) supports owning the franchise, but the absence of fresh upgrades after the gap argues for patience rather than chasing.
Supporting evidence is strong on quality and moderate on price. Revenue rose 9.86% YoY to $1.214 billion in Q3 2026, with gross margin expanding from 60.35% in Q4 2025 to 62.94% and net margin from 22.76% to 26.12%, while trailing FCF of $1.30 billion on a $54.2 billion market cap yields ~2.4% and funded $112.2 million of Q3 buybacks plus $120 million of debt repayment. However, valuation is the offset: 51.37x trailing and 40.04x forward earnings, 12.59x sales, 36.54x EV/EBITDA, and a 2.31 PEG ratio sit roughly 100%+ above the low-to-mid-20s PE and 3-5x sales of large-cap diagnostics peers, and the average target's ~6.1% upside is thin relative to the $470 low target's ~30.5% downside.
The biggest risks that could invalidate the thesis are a further margin-guidance cut (management already trimmed its margin forecast despite raising EPS), deceleration of recurring diagnostics below the current ~10% rate, and reliance on buybacks ($351.0M Q1, $346.8M Q2, $112.2M Q3) to support per-share growth against a lean $197.5 million cash balance and 1.167 current ratio. This Hold would upgrade to Buy on a pullback toward the $550-575 pre-gap consolidation zone (roughly 15-19% below current) or on evidence that Q3's 33.14% operating margin is durable with fresh analyst target increases above $750; it would downgrade to Sell if recurring growth slips below high-single digits or margins revert toward the 31.6% trailing level. Net verdict: fairly valued to modestly rich relative to its own mid-range historical band (51.4x trailing PE versus an 85.7x 2021 peak and 32.5x Q3 2026 trough) and clearly premium versus peers — a quality franchise at a full price, not a bargain.
Sign up to view all
IDXX 12-Month Price Forecast
IDEXX is a high-quality compounder whose fundamentals — ~10% recurring growth, expanding margins, 66% ROE, and $1.30 billion of FCF — justify a premium, but the recent 33% post-earnings gap has consumed most of the near-term upside, leaving the average target only ~6.1% above the current price. The trimmed margin outlook and reliance on buybacks introduce genuine uncertainty about the durability of per-share growth against a 40x forward multiple, and the wide $470-$810 target spread captures the disagreement. We are neutral with medium confidence: the base case (55%) sees consolidation toward the $717 average target, while the bear case (20%) carries 30%+ downside to the $470 low target if margins compress. We would upgrade to bullish on a pullback toward the $550-575 pre-gap zone or on fresh target increases above $750, and downgrade to bearish if recurring growth slips below high-single digits or margins revert toward 31.6%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IDEXX Laboratories, Inc.'s 12-month outlook, with a consensus price target around $717.17 and implied upside of +2.7% versus the current price.
Average Target
$717.17
14 analysts
Implied Upside
+2.7%
vs. current price
Analyst Count
14
covering this stock
Price Range
$470 - $810
Analyst target range
Coverage is solid with 12 analysts, and the distribution of 9 Buy, 4 Hold, and 1 Sell yields a consensus recommendation of "buy" (mean score of 2.14 on a scale where lower is more bullish). The average target price of $717.17 implies roughly 6.1% upside from the current $676.04, a modest gap that reflects how much of the bullish case has already been priced in by the recent 33% one-month rally; the consensus leans constructive but not aggressively so, and the average target sits below the 52-week high of $769.98, implying analysts see limited further multiple expansion from here. The target range is wide, from a low of $470.00 (about 30.5% downside) to a high of $810.00 (about 19.8% upside), a spread of roughly 72% of the current price that signals meaningful disagreement about the durability of margins and growth. The high target assumes the recurring diagnostics franchise sustains low-double-digit growth with margin recovery and continued multiple support, while the low target discounts margin compression, softer clinic visits, and de-rating toward the sector average. Institutional ratings show a stable-to-cautiously-constructive pattern, with UBS and Citigroup maintaining Neutral, Morgan Stanley, JP Morgan, and Barclays holding Overweight, and Stifel at Buy, but notably no recent upgrades, suggesting the post-earnings rally has run ahead of formal analyst revisions and that estimate and target increases may be needed to sustain momentum.
Bulls vs Bears: IDXX Investment Factors
The bull case currently has stronger evidence: ~10% recurring revenue growth, gross margin expansion to 62.94%, 66% ROE, $1.30 billion of trailing FCF, and a post-earnings re-rating that outpaced SPY by 38 points in a month are all hard, verifiable data points. The bear case rests less on fundamentals than on price: a 51.4x trailing PE and 12.6x sales embed a premium roughly double the diagnostics peer group, and the trimmed margin outlook plus heavy buyback reliance raise legitimate questions about the quality of per-share growth. The single most important tension is whether the Q3 margin peak is durable — if operating leverage holds and recurring diagnostics sustain low-double-digit growth, the premium is defensible; if margins compress toward the 31.6% trailing level while growth decelerates, the multiple has significant room to de-rate. The wide analyst target spread from $470 to $810 (roughly 72% of the current price) captures precisely this disagreement, and the absence of fresh upgrades after a 33% rally suggests the market has priced in the near-term good news ahead of formal estimate revisions.
Bullish
- Recurring diagnostics compounding near 10%: Q3 2026 revenue of $1.214 billion rose 9.86% YoY from $1.105 billion, and the quarterly progression ($1.141B Q1, $1.217B Q2, $1.214B Q3) shows consistent high-single-digit compounding rather than a one-off spike. The mix of $722.9 million product and $491.4 million service revenue confirms the razor-and-blade flywheel is intact, with consumables and reference-lab work providing durable recurring income.
- Elite margins with genuine operating leverage: Gross margin expanded from 60.35% in Q4 2025 to 62.94% in Q3 2026, and net margin climbed from 22.76% to 26.12% over the same span, with Q3 operating income of $402.3 million at a 33.14% operating margin. ROE of 65.99% and ROA of 26.70% are exceptional returns on capital for the diagnostics industry.
- Post-earnings re-rating on raised EPS guide: The stock gapped from $551.21 on October 30 to $671.64 on November 2 after Q3 results, a 33.43% one-month move that outpaced SPY by 38.42 percentage points. That violent gap typically signals a fundamental re-rating rather than technical drift, and it came alongside a raised EPS outlook.
- Self-funding cash generation and buybacks: Trailing free cash flow of $1.30 billion against a $54.2 billion market cap implies a ~2.4% FCF yield, and Q3 FCF of $420.8 million covered $28.9 million of capex while funding $112.2 million of buybacks and $120 million of debt repayment. Aggressive repurchases ($351.0M Q1, $346.8M Q2) directly support per-share EPS growth.
Bearish
- Valuation priced for perfection: At 51.37x trailing and 40.04x forward earnings, 12.59x sales, and 36.54x EV/EBITDA, IDEXX trades at roughly a 100%+ premium on earnings and 150%+ on sales versus large-cap diagnostics peers in the low-to-mid-20s PE and 3-5x sales range. A 2.31 PEG ratio means the market pays more than two turns of multiple per point of growth, leaving no room for execution missteps.
- Margin outlook trimmed despite headline beat: Management raised EPS guidance but cut its margin forecast in the Q3 print, raising questions about whether the 33.14% Q3 operating margin is a sustainable peak. The Motley Fool flagged that the margin cut and reliance on financial engineering raise sustainability questions, a direct challenge to the operating-leverage thesis.
- Buybacks masking organic EPS quality: Repurchases of $351.0 million in Q1, $346.8 million in Q2, and $112.2 million in Q3 support EPS but invite the financial-engineering critique. With a lean cash balance of $197.5 million and a current ratio of 1.167, the company depends on operating cash flow rather than a cushion, so any FCF stall would undercut the per-share growth story.
- Rally has run ahead of analyst revisions: The 33% one-month surge leaves the average target of $717.17 only ~6.1% above the current $676.04, and the average sits below the $769.98 52-week high, implying limited further multiple expansion. Notably, no recent upgrades have been issued, with UBS and Citigroup at Neutral, suggesting targets and estimates may need to rise to sustain momentum.
IDXX Technical Analysis
IDEXX is in a recovery trend within a broader range, with the stock up 5.33% over the trailing year but still 12.2% below its 52-week high of $769.98 and 35.0% above its 52-week low of $500.61, placing the current $676.04 price at roughly 65% of the 52-week range. That mid-to-upper range positioning reflects a stock that has repaired much of a prior drawdown (max drawdown of -34.17%) without yet reclaiming leadership, and the -5.28% one-year return versus a +9.59% SPY gain leaves relative strength at -14.87% over twelve months, confirming a laggard that is now attempting to close the gap. The trend structure is constructive but not yet a confirmed breakout, since the price remains well shy of the prior high despite the sharp recent advance. Short-term momentum is decisively positive and sharply divergent from the muted one-year trend: the stock is up 33.43% in the past month and 15.23% over three months, with the one-month move outpacing SPY by 38.42 percentage points (relative strength of +38.42 versus SPY's -4.99%). The bulk of that gain came in a single violent gap from $551.21 on October 30 to $671.64 on November 2 following the Q3 report, a move that typically signals a fundamental re-rating rather than a technical drift, though such gaps often invite short-term consolidation. Six-month performance of +20.70% and year-to-date +0.90% show the recovery is recent and concentrated, and the elevated short ratio of 3.68 suggests short covering may have amplified the rally, which raises the risk of a momentum fade if follow-through volume (589,101 shares) does not persist. Key resistance sits at the $769.98 52-week high, roughly 13.9% above the current price, and a decisive break above that level would confirm a new uptrend and likely trigger momentum-fund accumulation; support is anchored at the $500.61 52-week low, about 26% below current levels, with intermediate support near the $550 pre-gap consolidation zone. A beta of 1.536 means the stock is roughly 54% more volatile than the market, so a 10% SPY drawdown could translate to a 15%+ decline here, which argues for smaller position sizing and wider stops; the -34.17% max drawdown over the past year is a concrete reminder of that amplified downside risk.
Beta
1.54
1.54x market volatility
Max Drawdown
-34.2%
Largest decline past year
52-Week Range
$501-$770
Price range past year
Annual Return
-2.2%
Cumulative gain past year
| Period | IDXX Return | S&P 500 |
|---|---|---|
| 1m | +34.2% | -2.7% |
| 3m | +26.7% | -2.5% |
| 6m | +32.0% | +2.4% |
| 1y | -2.2% | +10.8% |
| ytd | +4.2% | +11.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IDXX Fundamental Analysis
Revenue is growing at a healthy, stable clip rather than accelerating: Q3 2026 revenue of $1.214 billion rose 9.86% year over year from $1.105 billion, and the sequential progression from $1.141 billion in Q1 to $1.217 billion in Q2 to $1.214 billion in Q3 shows a business compounding in the high-single to low-double digits with modest seasonality. The mix is balanced between product revenue of $722.9 million and service revenue of $491.4 million, with recurring diagnostics and reference-lab services providing the durable growth engine while instrument and consumable sales supply the installed-base flywheel. The trajectory implies a roughly $4.8 billion annualized run-rate against consensus FY revenue estimates near $6.74 billion, and the consistency of ~10% growth across quarters supports the thesis that veterinary diagnostic frequency and pricing are offsetting softer clinic-visit volumes. Profitability is robust and improving: Q3 2026 net income of $317.1 million on a 26.1% net margin, gross margin of 62.94%, and operating margin of 33.14% (operating income of $402.3 million) reflect a high-quality, capital-light model. Gross margin has expanded from 60.35% in Q4 2025 to 62.94% in Q3 2026, and net margin has climbed from 22.76% to 26.12% over the same span, evidence of genuine operating leverage even as the company flagged a softer margin outlook. The 31.6% trailing operating margin and 24.6% net margin are exceptional for the diagnostics industry and reflect pricing power and scale, though the recent guidance trim warrants monitoring for whether the Q3 peak margin proves sustainable. The balance sheet is solid and cash-generative: debt-to-equity of 0.671, current ratio of 1.167, and trailing free cash flow of $1.30 billion against a $54.2 billion market cap imply an FCF yield of roughly 2.4%, while ROE of 65.99% and ROA of 26.70% are elite returns on capital. Quarterly free cash flow of $420.8 million in Q3 covered $28.9 million of capex and funded $112.2 million of buybacks plus $120 million of debt repayment, demonstrating self-funding capacity, though the low current ratio and modest cash balance of $197.5 million mean liquidity is lean and the company relies on operating cash flow rather than a cash cushion. Aggressive repurchases ($351.0 million in Q1, $346.8 million in Q2, $112.2 million in Q3) support EPS but also explain the financial-engineering critique in recent coverage, a risk if free cash flow growth stalls.
Quarterly Revenue
$1.2B
2026-09
Revenue YoY Growth
+9.9%
YoY Comparison
Gross Margin
62.9%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IDXX Overvalued?
Because IDEXX is solidly profitable (Q3 net income of $317.1 million), the PE ratio is the appropriate primary metric: the stock trades at 51.37x trailing earnings versus 40.04x forward, a 22% compression that implies the market expects meaningful EPS growth, consistent with consensus FY EPS estimates of $24.79 versus the current run-rate. The forward multiple of 40x on ~$24.79 of expected EPS is still rich in absolute terms, and the 2.31 PEG ratio suggests the market is paying more than two turns of multiple for each point of growth, leaving little room for execution missteps. On secondary metrics the stock is expensive across the board: 12.59x sales, 33.75x book, 45.99x cash flow, and 36.54x EV/EBITDA, all consistent with a premium-quality compounder rather than a value opportunity. Relative to the broader medical diagnostics and research sector, IDEXX commands a substantial premium, with a 51.4x trailing PE and 12.6x PS far above the low-to-mid-20s PE and 3-5x sales typical of large-cap diagnostics peers, a spread of roughly 100%+ on earnings and more than 150% on sales. That premium is defensible on quality grounds, given 62.9% gross margins, 33.1% operating margins, 66.0% ROE, and a dominant competitive position, but it also means the stock is priced for perfection and vulnerable to any deceleration in the ~10% growth rate. Against its own history, the current 51.4x trailing PE sits mid-range: well below the 85.7x peak in Q4 2021 and the 59.3x of Q4 2023, but above the 32.5x trough recorded in Q3 2026 and the 39.3x of Q4 2024, while the 12.6x PS is near the low end of its multi-year 32x-70x band. The takeaway is that valuation has de-rated substantially from pandemic-era excess and now sits in the middle of its historical band, suggesting the market is pricing in solid but not heroic expectations, with the recent 33% rally having already captured much of the near-term re-rating.
PE
51.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 31x~59x
vs. Industry Avg
35.2x
Industry PE ~35.2x*
EV/EBITDA
36.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on margin durability and the quality of per-share growth. Management raised EPS guidance but trimmed its margin forecast in Q3, and the 33.14% operating margin and 62.94% gross margin represent a peak versus the 31.6% trailing operating margin and 60.35% gross margin in Q4 2025, so any reversion compresses earnings against a 40.04x forward multiple. Buybacks of $351.0 million, $346.8 million, and $112.2 million across the first three quarters of 2026 support EPS but consume cash that could otherwise buffer a downturn, and with only $197.5 million of cash against a 1.167 current ratio, liquidity is lean and dependent on continued operating cash flow. Revenue is also concentrated in companion-animal diagnostics, so a sustained softening in veterinary clinic visits would hit both instrument placements and the high-margin consumable pull-through simultaneously. Market and competitive risks are dominated by valuation compression. At 51.37x trailing earnings, 12.59x sales, and 36.54x EV/EBITDA, IDEXX trades at roughly double the low-to-mid-20s PE and 3-5x sales typical of large-cap diagnostics peers, and a 2.31 PEG ratio leaves little tolerance for deceleration below the current ~10% growth rate. The stock's beta of 1.536 amplifies sector rotation risk, and the recent 33.43% one-month rally — with the average analyst target of $717.17 now only ~6.1% above the $676.04 price and no fresh upgrades from UBS, Citigroup, or the Overweight-rated banks — means the stock is vulnerable to profit-taking if follow-through volume of 589,101 shares does not persist. Competitive disruption from in-house lab consolidation or pricing pressure on reference-lab services would compound a multiple that already assumes sustained leadership. The worst-case scenario is a margin-guidance cut followed by decelerating recurring diagnostics growth, which would force analysts to cut estimates and compress the multiple toward the sector average. In that chain, the stock could retrace toward the $500.61 52-week low, roughly 26% below the current $676.04, and the analyst low target of $470.00 implies about 30.5% downside. A repeat of the -34.17% max drawdown recorded over the past year would take the shares to roughly $445, so an investor should size positions for a realistic -26% to -34% adverse outcome rather than treating the post-earnings gap as a floor.
FAQ
The most severe risk is margin durability: management raised EPS guidance but trimmed its margin forecast in Q3, and the 33.14% operating margin and 62.94% gross margin are peaks versus the 31.6% trailing operating margin and 60.35% gross margin in Q4 2025, so reversion would compress earnings against a 40.04x forward multiple. Second is valuation compression — at 51.37x trailing earnings and 12.59x sales, roughly double diagnostics peers, a de-rating toward the low-to-mid-20s peer PE implies downside toward the $470.00 analyst low target, about 30.5% below the current price. Third is growth deceleration: revenue is compounding at 9.86% YoY, and a slip below high-single digits as veterinary clinic visits soften would hit both instrument placements and high-margin consumable pull-through. Fourth is balance-sheet and quality-of-earnings risk — buybacks of $351.0 million, $346.8 million, and $112.2 million across Q1-Q3 2026 support EPS but leave only $197.5 million of cash against a 1.167 current ratio, and a beta of 1.536 means a 10% SPY drawdown could translate to a 15%+ decline, consistent with the -34.17% max drawdown of the past year.
The 12-month outlook splits into three scenarios. The base case (55% probability) targets $700-$740, assuming revenue growth holds in the high-single to low-double digits, gross margin stays at 61-63%, and the stock consolidates its 33% gap toward the $717.17 average analyst target as EPS grows toward the $24.79 consensus. The bull case (25%) targets $769.98-$810.00, requiring the Q3 33.14% operating margin to prove durable, low-double-digit recurring growth to persist, and fresh upgrades above $750 from the Overweight-rated banks. The bear case (20%) targets $470-$550, driven by a margin-guidance cut, decelerating recurring diagnostics, and multiple de-rating toward the low-to-mid-20s peer PE, retracing toward the $500.61 52-week low. The base case is most likely, and its key assumption is that the Q3 margin peak holds without a further guidance cut — the single variable that most changes the outcome.
IDXX screens as fairly valued to modestly rich on its own history but clearly premium versus peers. The 51.37x trailing PE sits mid-range within its multi-year band — below the 85.7x 2021 peak and 59.3x in Q4 2023, but above the 32.5x Q3 2026 trough and 39.3x in Q4 2024 — while the 12.59x PS ratio is near the low end of its historical range. Against large-cap diagnostics peers trading at low-to-mid-20s earnings and 3-5x sales, IDEXX commands roughly a 100%+ earnings premium and 150%+ sales premium, reinforced by 36.54x EV/EBITDA, 33.75x book, and a 2.31 PEG ratio. The 40.04x forward PE versus 51.37x trailing implies the market expects meaningful EPS growth toward the $24.79 consensus, a 22% multiple compression that is achievable but leaves little slack. In short, the market is paying a full price for quality — the valuation implies sustained ~10% growth and durable 62-63% gross margins, and any shortfall would likely be met with multiple compression rather than tolerance.
From a risk/reward standpoint the setup is balanced rather than compelling at $676.04. The upside to the $717.17 average analyst target is only about 6.1%, while the $470.00 low target implies roughly 30.5% downside and the $500.61 52-week low sits about 26% below the current price — an asymmetry that argues against chasing after a 33.43% one-month rally. The quality case is genuine: 9.86% revenue growth, 62.94% gross margin, 65.99% ROE, and $1.30 billion of trailing free cash flow support the premium, and the 9 Buy versus 4 Hold and 1 Sell consensus (mean score 2.14) confirms institutional confidence. The biggest downside risk is a second margin-guidance cut that would expose the 40.04x forward PE to de-rating toward the low-to-mid-20s peer multiple. It is a reasonable buy for long-term investors who can tolerate a 1.536 beta and a -34.17% historical drawdown, ideally accumulating on a pullback toward the $550-575 pre-gap zone; momentum traders should wait for a confirmed break above $769.98 or fresh upgrades above $750.
IDXX is best suited to long-term holding, with a suggested minimum horizon of 2-3 years. The business is a mature, high-quality compounder — roughly $4.8 billion annualized revenue, 9.86% YoY growth, 65.99% ROE, and $1.30 billion of trailing free cash flow — whose value accrues through earnings compounding rather than a dividend, since the payout ratio and yield are both 0%. Short-term trading carries elevated risk: the beta of 1.536 amplifies market moves, the -34.17% max drawdown over the past year shows the downside amplitude, and the 33.43% one-month gap from $551.21 to $671.64 on November 2 typically invites consolidation, with a short ratio of 3.68 suggesting short covering may have amplified the move. Earnings visibility is reasonably good given consistent quarterly revenue progression ($1.141B Q1, $1.217B Q2, $1.214B Q3), but the trimmed margin outlook introduces near-term uncertainty that favors patience over tactical positioning. Investors should size positions for a realistic -26% to -34% adverse outcome and consider staging entries rather than committing fully at $676.04.